The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in the US, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

The Immunology Drug Product Portfolio contains Drug Classifications, Product Assessment, Data by Company, Price Analysis by Retail and Veteran Discounts for biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI®.

This market report includes a detailed analysis of the drugs used to treat psoriasis in the US, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis in the US, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in the US, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat Crohn’s disease in the US, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat Crohn’s disease in Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis in Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat psoriasis in Europe, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

The Immunology Drug Product Portfolio contains Drug Classifications, Product Assessment, Data by Company, Price Analysis by Retail and Veteran Discounts for biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI®.

The psoriasis treatment market includes all over-the-counter and prescription pharmaceutical products used to treat psoriasis. This includes topical tar, salicylic acid, corticosteroids, combination corticosteroids, vitamin D analogs, anthralin, retinoids, methotrexate, cyclosporine, and biologic treatments.